Status:

COMPLETED

Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study

Lead Sponsor:

Sheffield Teaching Hospitals NHS Foundation Trust

Conditions:

Acquired Immune Deficiency Syndrome Virus

Eligibility:

All Genders

18-49 years

Phase:

PHASE2

Brief Summary

Influenza ('flu) can cause severe infections, especially in people with weakened immune systems such as those with HIV. For this reason, yearly vaccination is recommended with the standard 'inactivate...

Detailed Description

The emerging field of systems vaccinology offers an unbiased, global approach to studying immune responses to vaccines, unlike the traditional reductionist approaches that focus on specific arms of th...

Eligibility Criteria

Inclusion

  • Age18 - 49
  • HIV1 infected
  • On antiretroviral therapy
  • CD4 count of \>200/mm3 (for at least 6 months, last available measurement within 3 months)
  • Viral load undetectable (for at least 6 months, last available measurement within 3 months)
  • Historyof having received at least one dose of trivalent inactivated influenza vaccine in the past
  • Nonsmoker

Exclusion

  • Severe egg allergy
  • Hypersensitivity to gentamicin
  • Pregnant or breastfeeding
  • Chronic lung disease (e.g. bronchiectasis)
  • A history of severe asthma or current active wheezing
  • Other cause for immunosuppression (e.g. malignancy) or immunosuppressive medication
  • Hepatitis B or C coinfection (as defined by a detectable HBSAg or HCV RNA)
  • Planned close contact with severely immunocompromised individuals in 2 weeks following LAIV (e.g bone marrow transplant recipients)
  • Recipient of any other vaccination within the last 4 weeks
  • Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks.
  • Individuals with a known and current history of anaemia or any symptoms (shortness of breath, chronic fatigue, chest pain or pallor) suggestive of possible anaemia or haemoglobin below the lower limit of sex adjusted normal range on a full blood count taken within the last 3 months.
  • Current(active) participation in any clinical trial
  • Inability to communicate in English or convey willingness to participate.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2015

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT02266992

Start Date

September 1 2014

End Date

June 1 2015

Last Update

March 21 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sheffield Teaching Hospitals NHS Foundation trust

Sheffield, South Yorkshire, United Kingdom, S10 2JF